OraSure Technologies, Inc. (OSUR)

OraSure Technologies' stock price has declined by 32.35% between January 8, 2025, and January 7, 2026. Key events include Q3 2025 financial results, where the company reported $27.1 million in total revenue and a GAAP operating loss of $16.1 million, projecting a return to growth in 2026. Altai Capital expressed intent to nominate director candidates, and OraSure submitted FDA applications for STI tests, leading to a 3.8% share gain.

OraSure Technologies' demand seasonality is influenced by factors in its diagnostics and sample management segments. Gross margin percentage is expected to be slightly lower in Q4 due to typical seasonality and a greater mix of international revenue. Demand for COVID-19 PCR testing declined significantly in 2022 and 2023. Infectious disease testing may experience consistent demand, while at-home STI testing could introduce new demand patterns. Molecular sample management solutions might have demand patterns tied to research cycles and funding.

OraSure Technologies, Inc. is a medical device company specializing in point-of-care and home diagnostic tests, sample management solutions, and microbiome laboratory services. The company aims to improve healthcare access through innovative testing solutions. OraSure's product portfolio includes diagnostic products like rapid tests for HIV, Hepatitis C, Ebola, Zika virus, and influenza, as well as sample management solutions like Oragene and OMNIgene collection kits.

OraSure Technologies serves a global market through various channels, including clinical laboratories, hospitals, and direct-to-consumer sales. The company has a focus on Sub-Saharan Africa for HIV testing initiatives. OraSure's headquarters and main manufacturing facility are located in Bethlehem, Pennsylvania, USA. Its subsidiaries, DNA Genotek Inc. and Sherlock Biosciences, have operations in Ottawa, Canada, Newton, Massachusetts, and the United Kingdom.

OraSure Technologies aims to be a transformative force in healthcare through innovation in testing and sample management. Strategic acquisitions, such as Sherlock Biosciences, and investments in next-generation diagnostics, like Sapphiros, enhance its reputation as an innovator. FDA submissions for STI tests highlight the company's efforts to provide accessible healthcare solutions. While financial performance in 2025 reflects a transition year, a strong balance sheet supports future growth and maintains investor confidence.

OraSure Technologies is a publicly traded company on Nasdaq (OSUR). Institutional investors hold a majority of the shares, with 359 institutional owners holding 93.50% of total institutional ownership as of August 2025. Major institutional shareholders include BlackRock, Inc., Private Management Group Inc, and Neuberger Berman Group LLC. Approximately 4.98% of the company's stock is held by insiders, and 35.24% by public companies and individual investors.